2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Gene Editing, Treatment Considerations, Drug Development, Supportive Care, Biological Therapies, Gene Therapy, Workforce, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, GVHD, GVD, Immunodeficiency, Neutropenia, White Blood Cell Disorders, Research, Fundamental Science, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

6125 Investigating perceptions of access and factors functionally limiting access to gene therapy for sickle cell disease (SCD): A mixed method study of SCD-focused hematologists in the midwest

Kristin Weeks, MD, PhD, Nicole Thomas, PhD, MS2, Alice A Gaughan, MS3, Ann Scheck McAlearney, ScD, MS4
1 The Ohio State University, columbus, Ohio, United States
2 The Ohio State University, columbus, Ohio, United States
3 The Ohio State University, columbus, Ohio, United States
4 The Ohio State University, columbus, Ohio, United States

Introduction

In December 2023, two ex vivo gene therapies were approved by the Food and Drug Administration (FDA) for the functional cure of sickle cell disease (SCD). Since then, access to gene therapy has been hypothesized to be limited by the high cost of the therapy, limited manufacturing capacity, and a scarce number of centers with the expertise and resources to offer gene therapies. The Midwest has few SCD centers of excellence and a high number of patients with SCD. We aimed to explore the viewpoints of SCD-focused hematologists in the Midwest on access to gene therapy and factors limiting access to gene therapy.

Methods

We utilized a mixed method approach. SCD-focused hematologists were identified by searching public health department, SCD organization, and healthcare center websites. We recruited all SCD-focused hematologists caring for the adult patient population and practicing in 5 Midwestern states (i.e., Illinois, Missouri, Indiana, Kentucky, and Ohio) to participate in our interview study from September to November of 2025 through their work emails. SCD-focused hematologists who enrolled in our interview study completed a virtual, recorded, telephone interview. We used a semi-structed interview guide to conduct the interviews, and inductive and deductive approaches in our qualitative analysis of the interview transcripts. To quantify the experiences of SCD-focused hematologists, we recruited all SCD-focused hematologists practicing in the 11 states of the Midwest to our survey study from May to June 2026 through their work emails. SCD-focused hematologists who participated in our survey study completed a virtual, Qualtrics-based, 20-question survey. SAS and Excel were used to analyze the survey results.

Results

We reached saturation of themes in 11 interviews and a response rate of 48% (i.e., 44 responded of 91 recruited) for our survey study. Interviewed SCD-focused hematologists reported limited availability of gene therapy. In surveys, only 52% of SCD-focused hematologists reported gene therapy was available to their patients with SCD. This reported availability of gene therapy was substantially lower than the reported availability of non-curative therapies including opioids (89%), hydroxyurea (86%), Adakveo (84%), and Endari (82%).

The factors identified that functionally limited gene therapy for many SCD-focused hematologists included patient concerns about infertility (reported by 75% of surveyed SCD-focused hematologists), limited insurance coverage (68%), physician referral restriction due to low social support (66%) and a history of missed appointments (55%), limited access to fertility counseling (50%), the high cost of fertility preservation (43%), and distance to receive gene therapy (34%). SCD-focused hematologists reported varied driving distance barriers to gene therapy. For referrals, 43% reported referring to their own institution for gene therapy, 30% referred to a center over 1 hour away (i.e., by driving distance), and 12% had never made a referral to gene therapy for SCD.

Discussion

While the cost of therapy was not directly identified as a limiting factor, the lack of insurance coverage was identified as limiting access to gene therapy for the majority of SCD-focused hematologists who participated in our studies. In addition, the limited number of capable centers was also not directly identified as a limiting factor, but inequitable driving distances to receive gene therapy was identified as a barrier. Our study participants identified two novel barriers to gene therapy: concerns about fertility and concerns about patient adherence. Physicians identified a systemic lack of resources and insurance coverage for fertility preservation, and reported this impacted patient and provider openness to gene therapy. Physician participants reported potentially restricting referrals to patients who had little social support and/or a history of missed appointments. Significant efforts, such as developing partnerships and programs for patients facing distance barriers, providing standardized readiness and counseling for patient candidates, and offering affordable and accessible fertility preservation services are needed to ensure equitable access to gene therapy for patients with SCD. Future research incorporating patient perspectives will also be important to inform new programs and processes in actualizing the enormous potential value of gene therapies for patients with SCD.

Kristin Weeks, MD, PhD: No relevant conflicts of interest to declare.